Joseph Moore, MD
Medical Oncology · Wichita, KSNPI 1750777959
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (53.7%), food and beverage and speaking fees — rather than concentrated in one kind of arrangement. It is spread thinly across 60 manufacturers, the largest accounting for just 19.9%.
Across 933 payments — averaging $44.23 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Daiichi Sankyo Inc.$8K
- AbbVie$3K
- Pfizer$2K
- Beigene USA, Inc.$2K
- Janssen Global Services, LLC$2K
- AstraZeneca$2K
- plus $21K from 54 others
What the payments were for
- Consulting fees$22,15454%
- Speaking & faculty fees$2,4706%
- Food & beverage$16,50140%
- Education$1460%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$41,271 in reported general payments places this provider in the 75th percentile of 25 medical oncology providers in Kansas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| CabometyxCabozantinib S-Malate | 28 | $700,142 |
| Lenalidomide | 54 | $627,611 |
| RevlimidLenalidomide | 28 | $455,014 |
| JakafiRuxolitinib Phosphate | 25 | $426,396 |
| PomalystPomalidomide | 12 | $319,396 |
| BosulifBosutinib | 11 | $222,526 |
| NubeqaDarolutamide | 15 | $200,562 |
| VenclextaVenetoclax | 16 | $188,136 |
| ErivedgeVismodegib | 12 | $176,178 |
| ErleadaApalutamide | 12 | $158,318 |
| Abiraterone Acetate | 26 | $124,860 |
| EliquisApixaban | 99 | $60,268 |
| XareltoRivaroxaban | 35 | $24,165 |
| CreonLipase/Protease/Amylase | 16 | $19,976 |
| Letrozole | 198 | $5,799 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Exelixis Inc.Cabometyx | $313 | $700,14228 claims |
| Bristol Myers SquibbRevlimid | $581 | $455,01428 claims |
| Incyte CorporationJakafi | $246 | $426,39625 claims |
| E.r. Squibb & Sons, L.L.C.Pomalyst | $453 | $319,39612 claims |
| PfizerBosulif, Eliquis | $2,482 | $282,794110 claims |
| AbbVieVenclexta, Creon | $2,613 | $208,11232 claims |
| BayerNubeqa | $149 | $200,56215 claims |
| Johnson & JohnsonErleada, Xarelto | $669 | $182,48347 claims |
| Genentech USA, Inc.Erivedge | $376 | $176,17812 claims |
| Lilly USA, LLCOlanzapine | $382 | $2,248128 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 25 medical oncology providers in Kansas.
Other medical oncology in Wichita
- Anne OdeaWestwood$2.1M
- Benjamin GeorgeColby$433K
- Weijing SunWestwood$150K
- Anwaar SaeedWestwood$126K
- Elizabeth WulffWestwood$65K
- Anis ToumehGarden City$40K
- Ajjai AlvaOverland Park$25K
- Joaquina BarandaWestwood$18K
- Elshami ElaminNewton$17K
- Mark FesenGreat Bend$10K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.